Bureau BÍta Home page

5.48

Individual differences in the reaction of alcohol-dependent patients to Naltrexone: Psychological mechanisms and therapeutic effects

Institution/
contact address:

University Maastricht, Faculty of Psychology
PO Box 616, 6200MD Maastricht

Tel.: (043) 388 19 44

Contactperson/
researcher(s):

Dr. R.W. Wiers, dr. P. Batel, drs. E. van den Wildenberg, A. Dobbs MSc, & drs. T. Wijdeveld.

Goal of the study:

To identify predictors of a good response to the medication Naltrexone (NTX), an opioid receptor antagonist, against alcoholism. It is hypothesized that a positive family history, strong craving for alcohol and strong positive, arousal expectancies of alcohol predict a good response to the medicine. If this turns out to be true, subtypes of alcoholics can be treated more effectively.

Type of study:

Randomized clinical trial, multi-center, placebo-controlled, double-blind.

Research
questions:

Hypotheses:

NTX will reduce alcohol consumption more strongly than placebo. This effect is expected to be stronger in individuals with a positive family history (FHP) than in FHN (Family History Negative) alcoholics.

Alcoholics with strong craving will benefit more from NTX treatment than alcoholics with weak craving for alcohol.

Patients with strong positive arousal expectancies of alcohol will respond better to NTX than patients with wreak arousal expectancies.

Population
studied:

200 Alcohol dependent patients.

Design and
instruments:

The duration of treatment is 3 months with another 3 months follow-up in which no medication against addiction is taken. During those 6 months the patient is seen 9 times. To enhance compliance the motivational interview approach called BRENDA will be used.

Alcohol diary. Questionnaires: Expectancies, craving, motivation to change, antisocial behavior, BIS/BAS.

Startdate:

2002.

Duration:

3 years.

Initiative:

R. W. Wiers and P. Batel.

Collaboration:

Beaujon Hospital, Clichy, Paris, France.

Paschalis, Oostrum.

CAD Noord-Midden Limburg, Venlo

Funding:

ZonMw Netherlands Organisation for Health Research and Development.

Inserm, The French Institute of Health and Medical Research, Paris.

Results:

Not available yet.

Reporting:

Articles and dissertation.